Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nanocort (liposomal prednisolone) for treatment of Graves' orbitopathy
2017-001158-33Phase 2Completed
- Sponsor
- Het Oogziekenhuis Rotterdam
- Start
- Apr 2017
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, single-arm trial of hydrocortisone in Graves' ophthalmopathy (TED), sponsored by Het Oogziekenhuis Rotterdam. Primary endpoints: Treatment response at week 6 and Treatment response at week 13. Started Apr 2017; status: completed.
02
Drugs
hydrocortisone
03
Conditions
Graves' ophthalmopathy (TED)
Beyond the preview
Go deeper on 2017-001158-33.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2017-001158-33.